| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
|
| | JND3229 Basic information |
| Product Name: | JND3229 | | Synonyms: | JND3229;JND3229
(JND-3229;JND3229;JND-3229;JND 3229;Propanamide, N-[trans-4-[3-(2-chlorophenyl)-3,4-dihydro-7-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]cyclohexyl]-;N-(trans-4-(3-(2-Chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)cyclohexyl)propionamide;N-[(1r,4r)-4-[3-(2-chlorophenyl)-7-{[3-methyl-4-(4-methylpiperazin-1-yl)phenyl]amino}-2-oxo-1H,2H,3H,4H-[1,3]diazino[4,5-d]pyrimidin-1-yl]cyclohexyl]propanamide;JND3229, 10 mM in DMSO | | CAS: | 2260886-64-2 | | MF: | C33H41ClN8O2 | | MW: | 617.19 | | EINECS: | | | Product Categories: | | | Mol File: | 2260886-64-2.mol |  |
| | JND3229 Chemical Properties |
| density | 1.34±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO : 12.5 mg/mL (20.25 mM; Need ultrasonic) | | pka | 16.01±0.40(Predicted) | | form | Solid | | color | White to light yellow |
| | JND3229 Usage And Synthesis |
| Uses | JND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma[1]. | | in vivo | JND3229 (10 mg/kg; i.p.; twice daily for 10 days) exhibits an obvious suppression of tumor growth, and shows target inhibition in vivo[1]. | Animal Model: | BALB/c mice (bearing established BaF3-EGFR19D/T790M/C797S mouse xenograft tumors model)[1]. | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection; twice daily for 10 days. | | Result: | Caused an obvious suppression of tumor growth with a Tumor Growth Inhibition (TGI) value of 42.2%.
Showed well tolerance without obvious body weight loss or other obvious toxic sign in the treated animals.
Significantly decreased the level of phosphorylated EGFR (p-EGFR) tin the tumor tissues.
|
| | References | [1] Lu X, et al. Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy. ACS Med Chem Lett. 2018 Oct 8;9(11):1123-1127. DOI:10.1021/acsmedchemlett.8b00373 |
| | JND3229 Preparation Products And Raw materials |
|